It's Time for Medtech to Turn Digital

Posted by Pete Masloski on May 10, 2018

The digital health industry has had its share of hype over the years. Remember when fitness trackers were the next greatest thing, and billions of dollars were flooding through venture capitalists into new digital health startups that were going to make us all eat better and exercise more? Well, we know how that turned out: Fitbit recently announced its seventh consecutive quarter of year-over-year revenue declines as well as several new partnerships designed to bake their wearables into more comprehensive health management programs. It turns out that it takes a lot more than a clever device to change behavior. 


>
Read More

Stop Waiting for Data in Medtech. It’s Already Here.

Posted by Maria Kliatchko on April 18, 2018

When speaking with clients and colleagues about the promise of advanced analytics for medical device companies, I often hear that there’s not enough good data for analytics, or that internal data is patchy, incomplete, poorly defined and spread across many systems. Those with pharmaceutical experience complain of the lack of market data, such as physician-level prescription data sets used by pharma companies, which would allow medtech companies to have visibility into their own market share, along with full product usage and potential of their customers.


>
Read More

Home vs. Away: Lessons on Customizing Your Go-to-Market Game Plan

Posted by Lukas Grabner on March 9, 2018

During my time with ZS, I’ve had the opportunity to live and work both in Europe and the U.S. Once I returned to Europe last year after spending two years in our San Francisco office, I reflected a bit on the differences between the two markets and the typical challenges that our clients encounter when entering them.


>
Read More

Don’t Call It a Transformation: Four Takeaways From The Medtech Conference

Posted by Brian Chapman on February 20, 2018

This post is the first in a series on the evolution of the medtech commercial model.


I facilitated a panel last fall at The MedTech Conference (formerly the AdvaMed conference) and have continued to think about it. Subsequent conversations with leaders have made me want write down a few thoughts from the day. The panel was called “Driving Growth Through New Commercial Strategies” with medtech experts including Tim Schmid, chief strategic customer officer at Johnson & Johnson Medical Device Companies; Joe Gasque, CMO for the U.S. and Canada at GE Healthcare; and Vince Wong, vice president of strategy and communications at Roche Diagnostics. This group packed the room, and in my humble opinion, the audience seemed pretty engaged.


>
Read More

Planning Your Launch Amid the US/EU Regulatory Convergence

Posted by Kate Templeton on January 4, 2018

Dan Frey and Barun Maskara co-wrote this blog post with Kate Templeton. 

Five to 10 years ago, many medium- and high-risk medical devices were expected to be commercialized first in Europe, with U.S. approvals lagging years behind. Industry leaders often criticized the FDA for inconsistently enforcing sometimes unclear regulations, and lamented that the lengthy and unpredictable U.S. approval timelines were driving innovation overseas.


>
Read More